Efmitermant alfa

DB16686InvestigationalProtein Based Therapies

Efmitermant alfa, a locally-acting GDF/activin ligand trap, is under investigation in clinical trial NCT03124459 (Study of ACE-083 in Patients With Charcot-marie-tooth Disease).

Mechanism: Pharmacologically active on Growth/differentiation factor 8
Curator reviewed
Code names: ACE-083

Resolves to

Compound

UNII566QNS333VCAS1644543-31-6

Targets

O14793MSTN

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Efmitermant alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account